SecBot SecBot

BIIB drug pipeline

BIOGEN INC. · 11 rated drugs
$251.65
−0.7% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.9%
1-day, median of 17 events
IV rank
98
IV 49% · HV 33%
Rated drugs
11
3 bullish · 8 neutral
Phase 3 trials
6
2 with results posted

Upcoming catalysts

2 dated
  1. Dec 1, 2026
    felzartamab
    Phase 3 primary completion
  2. Dec 31, 2026
    Lecanemab IV
    Phase 3 primary completion

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3
Time to marketIf the PHOENYCS FLY study reads out positively in December 2026, regulatory submissions (BLA in the US, MAA in Europe) could follow in 2027, with potential approval in 2028-2029, assuming no additional trials are required.

dapirolizumab pegol Updated Nov 9

What to watch

The next hard catalyst is the Phase 3 PHOENYCS FLY topline readout, which Biogen guided for the first half of December 2026 on its Q3 earnings call. A positive result would strengthen the case for regulatory filings in SLE; a miss would raise doubts about the drug's profile despite PHOENYCS GO's success. Watch for the readout timing and any pre-announcement.

Bull case
  • The Phase 3 PHOENYCS GO study met its primary endpoint with statistical significance: 50% of patients achieved BICLA response at week 48 vs 35% on placebo (p<0.001), and results were published in The Lancet.
  • Additional data presented at ACR 2026 (Nov 9, 2026) and EULAR 2026 showed benefits across multiple endpoints including fatigue reduction, flare rate reduction, and steroid-sparing effects.
  • The drug targets CD40L via a novel Fc-free mechanism, which may offer a differentiated profile versus existing SLE biologics that target BLyS (Benlysta) or type 1 interferon receptor (Saphnelo).
Bear case
  • SLE is a notoriously difficult indication with a history of Phase 3 failures; a second confirmatory trial (PHOENYCS FLY) is still needed and could fail to replicate PHOENYCS GO's positive result.
  • The SLE market already has two approved biologics (GSK's Benlysta and AstraZeneca's Saphnelo, the latter recently approved for subcutaneous self-administration), meaning dapirolizumab pegol would face established competition if approved.
  • Biogen is a large-cap company with a diversified portfolio; dapirolizumab pegol is only one of several pipeline assets, so even a positive readout may have limited impact on BIIB shares.
▲ bullish
Impact
PhasePhase 3
Time to marketIf Phase 3 TOPAZ trials succeed, Biogen would likely file a BLA in 2027, with potential FDA approval in 2028 at the earliest, given the drug is still in Phase 3 with no filed application.

litifilimab Updated Oct 28

What to watch

The next major catalyst is the Phase 3 TOPAZ-1 and TOPAZ-2 topline readout for systemic lupus erythematosus, expected in the first half of December 2026 (roughly 5-7 weeks away). Positive data would validate litifilimab across both CLE and SLE and likely trigger a significant stock rally; negative or mixed results would be a major setback for Biogen's first lupus program and could erase the stock's recent gains tied to pipeline optimism.

Bull case
  • Litifilimab has already demonstrated positive Phase 2 data in both CLE (LILAC study published in NEJM) and SLE, and received FDA Breakthrough Therapy Designation for CLE in January 2026, signaling regulatory interest.
  • 52-week Phase 2 AMETHYST data (October 2026) showed 27.2% of patients achieved clear/almost clear skin, up from 19% at Week 24, with durable and deepening responses over time.
  • Analyst sentiment on Biogen has turned strongly positive: JP Morgan upgraded to Overweight (PT $300), Wolfe Research upgraded to Outperform (PT $300), and Wells Fargo raised to $310, with 29 of 43 analysts at Buy/Strong Buy.
Bear case
  • Phase 3 TOPAZ-1/TOPAZ-2 trials could fail to meet primary endpoints (SRI-4 at Week 52), as SLE is a notoriously difficult indication with high placebo response rates and multiple past Phase 3 failures.
  • Biogen is a late entrant to lupus; GSK's Benlysta and AstraZeneca's Saphnelo are already approved, and litifilimab would need to show a clear differentiation to capture market share.
  • The drug is still investigational with no filed BLA or PDUFA date; even if Phase 3 succeeds, regulatory filing, review, and potential commercialization are years away.
● neutral
Impact
PhasePhase 3
Time to marketIf the Phase 3 TRANSCEND data (expected H1 2027) are positive, a regulatory filing could follow in 2027-2028, with potential FDA decision in 2028-2029 at the earliest. For IgA nephropathy, a Phase 3 program would likely be needed, extending the timeline further. Felzartamab is still investigational with no regulatory submissions filed yet.

felzartamab Updated Oct 25

What to watch

Watch for the Phase 3 TRANSCEND topline data expected H1 2027, positive results would be a meaningful pipeline catalyst for BIIB but not transformative given the company's scale. Investors should monitor for any early signals on efficacy from conference presentations and analyst previews in the months leading up to the readout. The competitive landscape in AMR (imlifidase, complement inhibitors, CAR-T) also warrants attention as it could narrow felzartamab's potential market.

Bull case
  • No FDA-approved therapy exists for chronic antibody-mediated rejection (AMR) in kidney transplant, felzartamab could be first-in-class if TRANSCEND succeeds, addressing a significant unmet need
  • Biogen has invested heavily: ~$1.15B to acquire HI-Bio (the original developer), plus $100M upfront to TJ Biopharma for Greater China rights (up to $750M in milestones), signaling strong conviction and full global rights consolidation
  • The Apellis acquisition ($5.6B) gave Biogen a commercial nephrology infrastructure (EMPAVELI/SYFOVRE with $689M combined 2025 revenue), providing a ready sales channel for a potential felzartamab launch
Bear case
  • Phase 3 TRANSCEND results are still ~6-9 months away (H1 2027); with only 132 patients enrolled, any efficacy miss or unexpected safety signal would be damaging given the program's small dataset
  • The molecule (originally MOR202) was developed by MorphoSys for multiple myeloma but was never approved and ultimately discontinued in that indication, raising questions about the drug's fundamental profile
  • Competition is intensifying: several other mechanisms are in development for AMR (imlifidase, complement inhibitors, anti-CD19 CAR-T, anti-CD20 agents), and some may reach the market first
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the U.S. since October 6, 2025 for maintenance dosing. Starting-dose label expansion decision expected August 24, 2026.

IQLIK lecanemab-irmb Updated Jun 30

What to watch

Watch the August 24, 2026 PDUFA for the starting-dose sBLA. Approval would allow IQLIK to compete for new patients from day one, not just maintenance, potentially accelerating Leqembi's commercial inflection. Biogen stock is near 52-week highs ($219.72) with a consensus mean PT of ~$220, so much of the Leqembi upside may already be priced in; a CRL or further extension could trigger a pullback from current levels.

Bull case
  • First-to-market at-home anti-amyloid Alzheimer's treatment, IQLIK's autoinjector removes the infusion-clinic bottleneck that has limited Leqembi's uptake, potentially unlocking a much larger patient pool (source: TIME Best Inventions 2025, Eisai press release).
  • Starting-dose label expansion (PDUFA August 24, 2026) would allow IQLIK to compete for new patients from the start, not just maintenance, a much larger TAM. The FDA has raised 'no concerns to date regarding approvability' per the May 8, 2026 update (source: BioArctic/Morningstar).
  • Leqembi revenue is accelerating, JPY 88 billion (~$580M) in FY2025, with IQLIK launched only mid-year. Biogen's 2025 revenue reached $9.9B and the company raised guidance, with Leqembi as a key growth driver (source: Fierce Pharma, Eisai FY2025 report).
Bear case
  • Starting-dose PDUFA was already extended by 3 months (to August 24, 2026) because the FDA requested additional information as a 'major amendment', this increases binary risk that approval could be delayed further or come with restrictions (source: Biogen/Eisai May 8, 2026 press release).
  • Competition from Eli Lilly's Kisunla (donanemab), approved July 2024, which offers monthly IV dosing (vs bi-weekly IV for Leqembi). Lilly also has strong commercial infrastructure and may develop its own subcutaneous formulation (source: FDA, Nature Reviews Drug Discovery).
  • Boxed warning for ARIA (amyloid-related imaging abnormalities, brain swelling/bleeding) requires regular MRI monitoring, creating a logistical and access barrier that limits the addressable patient population (source: FDA label).
● neutral
Impact
PhasePhase 2 (topline readout complete; confirmatory Phase 3 announced but not yet started)
Time to marketUnknown and several years away — a confirmatory Phase 3 program has not even started; the completed Phase 2 CELIA trial's estimated overall completion is January 2029, so a registration and launch would come later than that if Phase 3 succeeds.

diranersen Updated Aug 17

What to watch

Watch for Biogen's announcement of the Phase 3 program design, start date, and endpoints, that will be the next share-moving event, but it is likely months away and not a binary. Near-term BIIB stock moves are driven mostly by the commercial franchises (LEQEMBI, SPINRAZA) and other pipeline news, not diranersen, so treat this as years-out call-option value rather than a trade catalyst.

Bull case
  • Mechanism validated on biomarker: CELIA reportedly cut CSF tau by ~50-65% across doses, the deepest tau reduction seen in Alzheimer's, per Biogen's July 14, 2026 AAIC release.
  • Cognitive signal: pre-specified analyses showed clinical slowing on CDR-SB (~26% at 60 mg), and Biogen framed CELIA as the first study to show both tau pathology reduction and cognitive benefit, a potentially complementary approach to anti-amyloid drugs like its own LEQEMBI.
  • Company conviction: despite the primary-endpoint miss, Biogen explicitly plans to advance diranersen to confirmatory Phase 3, signaling it sees enough signal to invest in the largest, most expensive trial phase.
Bear case
  • Primary endpoint missed: CELIA did not meet its primary endpoint assessing dose response on CDR-SB, the study's main statistical test failed, and the positive numbers are from secondary/pre-specified exploratory analyses, which historically have a poor track record of surviving Phase 3.
  • Invasive delivery: intrathecal (spinal) injections every few months are a heavy burden for patients/caregivers and a commercial disadvantage versus IV/subcutaneous anti-amyloid alternatives such as LEQEMBI's newly approved subcutaneous form.
  • Long, uncertain timeline: no Phase 3 start or readout date exists, and the CELIA study's estimated overall completion is January 2029, any approval is years away, and Alzheimer's Phase 3 programs have a high failure rate.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the US (February 2023) and EU (February 2024). Pediatric label expansion, if successful, would follow the BRAVE study readout, likely in 2028 or later.

SKYCLARYS omaveloxolone Updated Oct 28

What to watch

SKYCLARYS has no upcoming PDUFA or pivotal readout in the next 12 months. The Phase 3 BRAVE pediatric study (ages 2-15) completed enrollment in August 2026, but its 52-week primary endpoint means topline results are unlikely before late 2027. Watch for quarterly sales growth trajectory and any label-expansion updates from the BRAVE study as the next potential catalysts.

Bull case
  • First and only approved treatment for Friedreich's ataxia, a rare disease with high unmet need and no direct competitors
  • Strong commercial momentum: Q3 2026 revenue of $178.2 million (+34% year-over-year), making it a key growth driver for Biogen
  • Pediatric expansion via the Phase 3 BRAVE study could significantly expand the addressable patient population if successful
Bear case
  • Already approved with no near-term binary catalyst, limiting upside from this drug alone for Biogen's stock
  • Biogen is a diversified company (Leqembi, Spinraza, MS franchise, Apellis products) so SKYCLARYS is one of several growth drivers, diluting its impact on the stock
  • The BRAVE pediatric study results are likely 12+ months away, providing no imminent catalyst
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since December 2016; high-dose regimen approved March 2026

SPINRAZA nusinersen Updated Jun 30

What to watch

Watch SPINRAZA quarterly revenue trends and high-dose regimen adoption as a read on Biogen's legacy cash-flow stability. The drug still pulls in ~$1.5B/year but is declining ~12% YoY, while the newly approved high-dose label could slow erosion. The more impactful catalyst for BIIB stock over the next 12 months is likely LEQEMBI's Alzheimer's rollout and the Apellis acquisition integration, not SPINRAZA.

Bull case
  • The newly FDA-approved high-dose regimen (March 30, 2026) offers faster loading, less frequent maintenance dosing (every 4 months vs. 3), and was associated with improved motor function in the DEVOTE study, potentially extending SPINRAZA's competitive positioning against Evrysdi and Zolgensma.
  • SPINRAZA remains a ~$1.5B annual revenue stream with patent protection estimated to extend into the mid-2030s, providing Biogen with steady cash flow to fund pipeline programs like LEQEMBI and new acquisitions.
  • Early patient feedback on high-dose SPINRAZA has been positive, with reports of switchbacks due to enhanced efficacy, suggesting the label expansion may slow or reverse the drug's revenue decline.
Bear case
  • SPINRAZA revenue is declining ~12% YoY ($374M in Q1 2026) due to competition from Roche's oral Evrysdi and Novartis' one-time gene therapy Zolgensma, plus lumpy ex-U.S. shipment timing.
  • Biogen's legacy MS franchise is also under pressure from generics/biosimilars, and SPINRAZA is classified by Biogen as a 'legacy' product rather than a 'growth product,' signaling limited upside.
  • The high-dose approval followed a surprise FDA rejection in September 2025, highlighting regulatory risk; any safety signal or manufacturing issue with the new regimen could accelerate revenue decline.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since October 2019.

VUMERITY diroximel fumarate Updated Oct 28

What to watch

VUMERITY has no upcoming FDA catalyst; the next material event for Biogen is the litifilimab Phase 3 SLE readout expected in December 2026. For VUMERITY specifically, watch quarterly sales trends and any generic patent challenges as the 2033 loss-of-exclusivity date approaches.

Bull case
  • A real-world study published June 2026 found significantly lower MS relapse rates with VUMERITY versus Tecfidera, providing a clinical differentiation argument for physicians and payers.
  • VUMERITY was designed with improved gastrointestinal tolerability compared to Tecfidera, a key differentiator that supports patient adherence and switching.
  • Patent protection runs until at least 2033, with no generic diroximel fumarate currently on the market, giving Biogen several more years of exclusivity.
Bear case
  • VUMERITY Q3 2026 in-market sales fell 11% year-over-year to $192M, continuing a declining trend as the MS franchise faces payer pressure.
  • Tecfidera (dimethyl fumarate) has 17 AB-rated generic competitors in the U.S., creating extreme price competition in the fumarate class that pressures VUMERITY's pricing power.
  • Biogen's overall MS product revenue declined 13.4% YoY in Q3 2026, showing the broader erosion of the legacy MS portfolio.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized since May 2021. No pending approval for this drug in its current indication.

EMPAVELI pegcetacoplan Updated Oct 25

What to watch

Empaveli is now a mature asset inside Biogen's (BIIB) portfolio following the May 2026 Apellis acquisition. There is no imminent PDUFA or pivotal readout for this drug. Investors should focus on Biogen's quarterly PNH franchise revenue (Empaveli + pipeline) and the SYFOVRE sales trajectory (which drives CVR payouts for former Apellis shareholders) rather than expecting a binary stock-moving event from Empaveli specifically.

Bull case
  • Empaveli is a first-in-class C3 inhibitor that blocks the complement cascade upstream of C5, offering a differentiated mechanism vs. Soliris/Ultomiris that may capture patients with suboptimal response to C5 inhibitors.
  • The drug contributes to Biogen's post-acquisition revenue diversification beyond its core neurology franchise (MS, Spinraza, Leqembi), adding a complement-mediated hematology/ophthalmology platform.
  • Biogen's commercial infrastructure and global reach could expand Empaveli's market penetration beyond what Apellis could achieve alone. BIIB analyst consensus skews buy (29 buy/strongBuy out of 43 analysts).
Bear case
  • Empaveli faces entrenched competition from Alexion/AstraZeneca's Soliris (eculizumab) and Ultomiris (ravulizumab), which are well-established C5 inhibitors with strong PNH market share and long safety track records.
  • The August 2026 FDA safety labeling update added a boxed warning for serious/fatal encapsulated bacterial infections, which could dampen prescriber confidence and patient uptake.
  • As a single product within Biogen's large portfolio (FY2026 consensus revenue ~$10.4B), Empaveli has limited ability to move BIIB's stock price meaningfully.
● neutral
Impact
PhaseApproved (accelerated approval)
Time to marketAlready approved and commercially available in the US (since April 2023) and EU (since May 2024), plus 42 other countries.

QALSODY tofersen Updated Oct 28

What to watch

The next hard catalyst for QALSODY is the ATLAS Phase 3 confirmatory trial readout, but its estimated primary completion is August 2027, more than 12 months away. With no imminent PDUFA or pivotal readout, QALSODY is unlikely to drive a major standalone move in BIIB shares in the near term. Watch for quarterly sales growth trajectory and any updates on the ATLAS enrollment or potential interim analysis.

Bull case
  • QALSODY is the first and only approved treatment targeting a genetic cause of ALS, a major scientific breakthrough. Long-term data published in JAMA Neurology (December 2025) showed early treatment with tofersen slows functional decline and reduces neurofilament light (NfL) over 2+ years, with some patients experiencing symptom reversal.
  • The drug has received approval in 44 countries, including the US (accelerated approval April 2023) and EU (May 2024), with expanding global reimbursement. Biogen's 2025 annual report noted QALSODY revenue 'grew notably' in 2025, driven by strong demand.
  • The ongoing ATLAS trial is the first-ever interventional study in presymptomatic SOD1 mutation carriers. If positive, it could expand the treatable population and potentially support conversion from accelerated to full FDA approval.
Bear case
  • QALSODY received only accelerated FDA approval based on a biomarker (NfL reduction), not on definitive clinical endpoints. The VALOR Phase 3 trial missed its primary endpoint (change in ALSFRS-R at 28 weeks), and continued approval depends on the ATLAS confirmatory trial, which is not expected to complete until 2028.
  • The addressable patient population is ultra-rare: roughly 2% of ALS cases carry an SOD1 mutation, or fewer than 5,000 patients globally. This caps peak sales potential; Q1 2026 global revenue was only $33M, a tiny fraction of Biogen's ~$10B annual revenue.
  • QALSODY is priced at ~$130,000/year and requires intrathecal administration (spinal injections), which limits patient access and requires specialized infusion centers.
● neutral
Impact
PhasePhase 1/2 (early-stage; Breakthrough Therapy Designation granted on interim Phase 1 results)
Time to marketUnknown — likely several years out. Early-stage (positive interim Phase 1 data), no Phase 2/3 timeline or PDUFA on file; Breakthrough designation can speed the FDA process but does not set a dated approval.

Salanersen Updated Jul 31

What to watch

Watch Biogen (BIIB) and partner Ionis (IONS) earnings calls and conference presentations for a dated Phase 2/3 start and efficacy/durability data for salanersen, the once-yearly dosing claim versus Spinraza's chronic dosing is the key thing to verify. Note that IONS already fell ~23% on July 9, 2026 on a separate Phase 3 failure (CARDIO-TTRansform), so salanersen news will have more relative impact on IONS than on BIIB; neither stock has a near-term salanersen-specific binary.

Bull case
  • FDA granted Breakthrough Therapy Designation for SMA, a regulatory validation of the preliminary efficacy/safety signal and an expedited development/review path (Biogen press release, June 4, 2026).
  • Differentiation potential: once-yearly dosing versus the chronic maintenance regimen of its in-house predecessor Spinraza (nusinersen), a meaningful convenience/competitive angle if the durability claim holds (Biogen press release, June 4, 2026).
  • Sits in Biogen's established SMA franchise, which it is actively expanding (high-dose nusinersen and salanersen were both on the March 2026 MDA/SMA Europe agenda), giving it commercial and medical infrastructure from day one.
Bear case
  • Very early stage: the designation rests on interim Phase 1 data; no Phase 2/3 topline readout or PDUFA is dated, so the next meaningful binary is likely more than 12 months away.
  • Crowded, competitive SMA market: approved Spinraza (Biogen's own), Evrysdi and Zolgensma (Novartis/Roche alternatives), plus Biogen's own high-dose nusinersen program, a new entrant must beat or complement existing standards.
  • Low concentration: salanersen is a minor program inside Biogen's large pipeline (LEQEMBI, Spinraza, Skyclarys, Apellis products, diranersen, etc.), so even good news moves BIIB little; on the Ionis side it is one of many partnered programs.

Other drugs in filings and trials

no drug report yet
  • LEQEMBI Last: PDUFA decision · May 24, 2026
  • TOFIDENCE Last: Approval · Sep 29, 2023
  • ZURZUVAE Last: Approval · Aug 4, 2023
  • ADUHELM Last: Approval · Jun 7, 2021
  • ZINBRYTA Last: Approval · May 27, 2016
  • PLEGRIDY Last: Approval · Aug 15, 2014
  • TECFIDERA Last: Approval · Mar 27, 2013
  • BG9418 (interferon beta 1-a) 1 trial
  • BIIB122 1 trial

Past FDA events & how the stock moved

17 events
DateDrugEvent1 day5 days
May 24, 2026LEQEMBIPDUFA decision−0.3%−0.8%
May 24, 2026LEQEMBIPriority review−0.3%−0.8%
Apr 29, 2026SPINRAZAApproval+3.2%+4.0%
Apr 3, 2026SPINRAZAPDUFA decision−2.8%−2.5%
Apr 3, 2026SPINRAZAApproval−2.8%−2.5%
Dec 31, 2025litifilimabBreakthrough designation+0.8%+5.4%
Jan 29, 2025litifilimabBreakthrough designation+0.5%+0.0%
Sep 29, 2023TOFIDENCEApproval−1.9%+2.1%
Aug 4, 2023ZURZUVAEApproval+1.3%+2.2%
Apr 25, 2023QALSODYApproval−1.7%+5.5%
Feb 28, 2023SKYCLARYSApproval+1.1%−1.6%
Jun 7, 2021ADUHELMApproval+38.2%+41.9%
Oct 29, 2019VUMERITYApproval+1.5%−1.1%
Dec 23, 2016SPINRAZAApproval+2.8%+3.0%
May 27, 2016ZINBRYTAApproval+2.7%+2.8%
Aug 15, 2014PLEGRIDYApproval+2.3%+0.9%
Mar 27, 2013TECFIDERAApproval+8.8%+10.5%

Clinical trials

12 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Lecanemab IVA Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's DiseasePhase 3Active not recruiting1,906Dec 31, 2026
felzartamabA Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)Phase 3Active not recruiting132Dec 1, 2026
SPINRAZAA Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)Phase 3Completed115Jul 30, 2026
—Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis PigmentosaPhase 3Completed277Jun 22, 2026
diranersenA Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgePhase 2Active not recruiting416May 14, 2026
BIIB122A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80Phase 2Completed650Mar 9, 2026
BIIB091A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)Phase 2Completed127Feb 10, 2026
dimethyl fumaratePhase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)Phase 3Completed · results156Jul 8, 2025
felzartamabClinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA NephropathyPhase 2Completed · results54Feb 6, 2023
Vascular Biogenics (VB)-111VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)Phase 2Terminated · results14Apr 12, 2022
Omaveloxolone Capsules, 2.5 mgA Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's AtaxiaPhase 2Completed · results172Oct 31, 2019
BG9418 (interferon beta 1-a)Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) PatientsPhase 3Terminated · results—Not stated